#1
|
|||
|
|||
Ñòåíòèðîâàíèå èíòðàêðàíèàëüíûõ àðòåðèé
Óâàæàåìûå êîëëåãè! ×åì áîëüøå ìû ðàáîòàåì ñ íåâðîëîãàìè, òåì ÷àùå ñòàëè ñòàëêèâàòüñÿ ñ ñèìïòîìíûìè ñòåíîòè÷åñêèìè ïîðàæåíèÿìè èíòðàêðàíèàëüíûõ àðòåðèé.
Íà äàííûé ìîìåíò èìååì: 1 - êîðîòêèé 90% ñòåíîç ñåãìåíòà Ì1 - ñèôîí îðäèíàðíûé; 2 - êîðîòêèé 85% ñòåíîç êëèíîèäíîãî ñåãìåíòà ÂÑÀ ñëåâà(îôòàëüìèêà íå êîíòðàñòèðóåòñÿ, ÏÌÀ íå êîíòðàñòèðóåòñÿ èç áàññåéíà ëåâîé, à çàïîëíÿåòñÿ èç ïðàâîé ïî ÏÑÀ ñ ñåãìåíòîì À1, ÇÌÀ èç áàññåéíà ïîçâîíî÷íîé, ñèôîí äâîéíîé) Íàøè íåáîãàòûå óìîçàêëþ÷åíèÿ ïîñëå ïðî÷òåíèÿ íåéðîðàäèîëîãèè, íî áåç îïûòà ñòåíòèðîâàíèÿ ÈÊÀ: 1. íàëè÷èå 85-90% ñòåíîçà è ÎÍÌÊ(ëàêóíàðíûå) â àíàìíåçå â áàññåéíå ñòåíîçèðîâàííîé àðòåðèè ÿâëÿåòñÿ ïîêàçàíèåì ê âìåøàòåëüñòó. 2. ñòåíòèðîâàíèå ÷åðåç 6 íåäåëü ïîñëå "ñîáûòèÿ" 3. ñòåíòèðîâàíèå êîðîíàðíûìè ñòåíòàìè - Des 4. 2-õ êîìïîíåíòíûå äåçàãðàãàíòû - íå ìåíåå 1 ìåñÿöà È áîëüøîé âîïðîñ - êàêèå ñòåíòû ëó÷øå äîñòàâëÿþòñÿ è ïî êàêîìó ïðîâîäíèêó? Ñïàñèáî! |
#2
|
||||
|
||||
èìõî:
ñóùåñòâóþò ñïåöèàëüíûå èíòðàêðàíèàëüíûå ñòåíòû, â ò.÷. è DES. íåéðîðàäèîëîãèÿ - îñîáàÿ "òåìà", ìàíèïóëÿöèîííûõ íàâûêîâ, ñêàæåì, ïåðèôåðè÷åñêîãî è êîðîíàðíîãî ñòåíòèðîâàíèÿ - íå äîñòàòî÷íî... íåïëîõî áû çíàòü íåâðîëîãè÷åñêóþ òîïèêó, ì.á. "ïðîó÷èòüñÿ" íà íåéðîõèðóðãà... è ïðîâîäíèêè - òîæå ñïåöèàëüíûå... Âû íå ïîäóìàéòå, ÷òî ÿ îòãîâàðèâàþ, íî "òåìà" ñëîæíåå, ÷åì êàæåòñÿ. Âçâåñüòå âñå "çà" è "ïðîòèâ"... âñå ÷èñòîå èìõî, êîíå÷íî... |
#3
|
||||
|
||||
Öèòàòà:
...Âîîáùå, ìîæåò ëó÷øå äîæäàòüñÿ ðåçóëüòàòîâ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]? Ñîâñåì íå î÷åâèäíî, ÷òî Wingspan îêàæåòñÿ ëó÷øå òàáëåòîê... Èïñèëàòåðàëüíûé èíñóëüò + ñìåðòü íà íåì ê 6 ìåñ - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ðåñòåíîç 25 - 30%. Ïðè òîì, ÷òî â WASID ÷àñòîòà èíñóëüòà òîëüêî "íà òàáëåòêàõ" 19% ïðè ñðåäíåì ïåðèîäå íàáëþäåíèÿ 1.8 ëåò... Îòãîâàðèâàþ. |
#4
|
|||
|
|||
Öèòàòà:
In a multivariable model that was adjusted for age, gender, and race, the risk of stroke in the territory of the stenotic artery was highest with severe stenosis 70% (hazard ratio 2.00, 95% CI 1.25 to 3.19, P=0.0026) and in patients enrolled early (17 days) after the qualifying event (hazard ratio 1.72, 95% CI 1.07 to 2.78, P=0.026). The WASID authors concluded that "these data indicate that intracranial stenosis is a high-risk disease for which alternative therapies are needed. Other options include aggressive management of risk factors, alternative antiplatelet regimens, and intracranial angioplasty or stenting. As yet, none of these treatments have been evaluated in a controlled clinical trial in patients with intracranial stenosis" (pp 1313–1314). Ò.å. ðèñê èíñóëüòîâ è äð. ïðîáëåì â ãðóïïå ñ âûðàæåííûì ïîðàæåíèåì èíòðàêðàíèàëüíûõ ñåãìåíòîâ åùå âûøå, ÷åì ñðåäíèå 18% (òàì, êàæåòñÿ, 24% íàñ÷èòàëè). Èìåííî òàêèå áîëüíûå ïðåäñòàâëåíû òàìáîâñêèìè êîëëåãàìè. ÈÌÕÎ, ýíäîâàñêóëÿðíîå ëå÷åíèå â ýòîì ñëó÷àå èìååò ïðàâî íà ñóùåñòâîâàíèå (èëè õîòÿ áû íà ðàññìîòðåíèå). Äà, ïî ãàéäàì 2009 ãîäà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] êëàññ äîêàçàòåëüíîñòè èíòðàêðàíèàëüíîãî ñòåíòèðîâàíèÿ ïîêà òîëüêî IIb, íî ðàíüøå âñå ýòè âåùè âîîáùå íå ðàññìàòðèâàëèñü! Endovascular revascularization by intravascular balloon angioplasty and/or stenting may be considered for patients with symptomatic severe intracranial stenoses (>70% luminal narrowing) despite optimal medical therapy (Class IIb, Level of Evidence C). Ê ñîæàëåíèþ, ïåðâûå ðåàëüíûå ðåçóëüòàòû SAMMPRIS áóäóò òîëüêî â àïðåëå, íàñêîëüêî ÿ ïîíèìàþ...èññëåäîâàíèå äîñòàòî÷íî âíóøèòåëüíîå, 50 öåíòðîâ, æäåì ñ íåòåðïåíèåì!  îáùåì, ìîæíî è ïîäîæäàòü ïàðó ìåñÿöåâ, ïðåæäå ÷åì Wingspan'û ñòàâèòü. Ïîâòîðþñü, íóæíî íà÷èíàòü íå ñàìèì, à ñ ïîìîùüþ ýêñïåðòîâ. Åñòü îäèí ìèíóñ - ýêñïåðòû ÿâëÿþòñÿ èíòåðâåíöèîííûìè íåéðîõèðóðãàìè, è îáû÷íî íå î÷åíü ïðèâåòñòâóþò, åñëè èíòðàêðàíèàëüíûå âìåøàòåëüñòâà õîòÿò îñâîèòü, íàïðèìåð, êàðäèîëîãè. Ëó÷øå, êîíå÷íî, åñëè â Òàìáîâå ýòîìó ïðîó÷àò ÷åëîâåêà ñ îïûòîì ðàáîòû â îòêðûòîé íåéðîõèðóðãèè. |
#5
|
|||
|
|||
Ê ñîæàëåíèþ, æåëàþùèõ ðàáîòàòü â ðåíòãåíîïåðàöèîííîé íåò â ïðèíöèïå! .
Ñëûøàë ÷òî â Ïèòåðå Ðåáÿòà ñòåíòèðóþò êîðîíàðíûìè DES (x....v). Äàæå äîñòàâëÿþò â áàçèëÿðíóþ. Åñòü ýë. Âåðñèÿ íåéðîðàäèîëîãèè, ãäå â ãëàâå ïðî ÈÊÑ òîæå ðåêîìåíäóþò DES íà áàëëîíå. Åñëè êîìó èíòåðåñíî, ìîãó îòïðàâèòü ïî email. Ïðîñòî õîòåëîñü óçíàòü ÷òî-íèáóäü ïî ïîäðîáíåå ó òåõ êòî äåëàåò ÈÊÑ. Âåäü òàêèå ëþäè åñòü ó íàñ? È ÷òî äåëàòü ñ ñèìïòîìíûìè áîëüøèìè ñòåíîçàìè? Æäàòü î÷åðåäíîãî (ïîñëåäíåãî) ÎÍÌÊ? |
#6
|
||||
|
||||
Öèòàòà:
|
#7
|
||||
|
||||
|
|
#8
|
|||
|
|||
Åñëè ÷åñòíî, ÿ äóìàþ, ÷òî àíãèîãðàôèþ îíè äåëàþò òîëüêî ðàäè îò÷¸òîâ.
Áóäåì ëå÷èòü... Êàê òîëüêî ïîÿâèòñÿ ÷òî-òî íîâåíüêîå â ýòîé èñòîðèè, ñîîáùó. |
#9
|
|||
|
|||
Interventional
NeuroradiologyStenting and Angioplasty for Intracranial Atherosclerotic Occlusive Disease Nabil M. Akkawi and Ajay K. Wakhloo Division of Neuroimaging and Intervention, University of Massachusetts Medical School, Worcester, Massachusetts, U.S.A.2008 Table 1 Inclusion Criteria for Intracranial Stenting >50% stenosis of a major intracranial vessel and refractory to medical treatment Minimum vessel diameter of 2.0 mm Previous stroke TIA Neurological symptoms referable to the target lesion Presence of symptoms during the 6 mo prior to treatment Acute vessel occlusion or dissection after PTA Abbreviations: TIA, transient ischemic attack; PTA, percutaneous transluminal angioplasty. Table 2 Exclusion Criteria for Intracranial Stenting Severe neurological deficit from stroke Chronic total occlusion History of intracranial hemorrhage, hemorrhagic stroke, major stroke, or any stroke with mass effect within 6 wk of procedure Contraindication for or resistant to antiplatelet therapy RESTENOSIS AFTER STENTING Stents may induce myointimal hyperplasia and restenosis (Fig. 5). The restenosis rate after stenting of ICD is approximately 10% to 13%. However, recently presented data from several centers showed that at 6- and 12-month follow-up angiography study, WingSpan self-expanding stents may have an incidence of up to 40% in-stent stenosis. To address these issues, stents coated with antiproliferative agents have been developed to reduce the in-stent stenosis and are being considered for the neurovascular system (58). Sirolimus (rapamycin), an antifungal agent, and paclitaxel, a microtubule inhibitor, have shown to prevent neointimal proliferation and restenosis in the coronary vessels when compared with bare metal stents (59). These clinical results provided the impetus to study the effect of antiproliferative agents for the intracranial system. Levy et al. studied the effects of heparincoated and sirolimus-eluting stents, which were implanted in canine basilar arteries (60,61). The mean percentage of stenosis 12 weeks after implantation was less (12%) in the group with heparin-coated stents compared with 22% in the group with uncoated devices. Compared with bare-metal stents, the sirolimus-coated devices did not impair endothelialization and, furthermore, tended to reduce the proliferation of smooth muscle cells. However, currently no single appropriate animal model exists for the study of intracranial atherosclerotic disease and of the effects of drug-eluting devices. |
#10
|
|||
|
|||
Öèòàòà:
Ó íàñ â ñòðàíå, íàñêîëüêî ÿ ñëûøàë, ýòèì íåìíîãî çàíèìàþòñÿ â Áóðäåíêî è â ÍÈÈ Ïîëåíîâà, âðîäå íåñêîëüêî ñäåëàëè â ÍÈÈ íåâðîëîãèè, Êðàñíîäàðå è Ñòàâðîïîëå, íî òî÷íî íå çíàþ, âîçìîæíî, èìååòñÿ â âèäó ïðîñòî ñòåíò-àññèñòåíöèÿ ïðè ýìáîëèçàöèè àíåâðèçì (áîëåå ÷àñòàÿ ïðîöåäóðà). Äóìàþ, îáùåå ÷èñëî ñòåíòèðîâàíèé èìåííî ïðè èíòðàêðàíèàëüíîì àòåðîñêëåðîçå ó íàñ â ñòðàíå âðÿä ëè ïðåâûøàåò 20-30,êàê ýòî íè ïå÷àëüíî. Òåì íå ìåíåå, òàêèå áîëüíûå åñòü, è íàäî èìè çàíèìàòüñÿ. Âîïðîñ, êòî áóäåò èìè çàíèìàòüñÿ? ß äóìàþ, ÷òî ïðàâèëüíåå, åñëè õèðóðã èñõîäíî áóäåò èìåòü äîñòàòî÷íî ãëóáîêèå çíàíèÿ àíàòîìèè è ôèçèîëîãèè ÃÌ, à òàêæå íåâðîëîãèè, ÊÒ è ÌÐÒ. Îñëîæíåíèé òîãäà áóäåò ìåíüøå, à åñëè îíè áóäóò - ýòîò æå õèðóðã ñóìååò èõ èñïðàâèòü îòêðûòûì ïóòåì. Ìîæíî, êîíå÷íî, è êàðäèîëîãà ïîä ýòî ïåðåó÷èòü, íî çàíèìàòüñÿ íåéðîõèðóðãèåé è êàðäèîëîãèåé îäíîâðåìåííî î÷åíü òðóäíî. Ïîïðîáóéòå, âîçìîæíî ó âàñ ïîëó÷èòñÿ. Ñ äðóãîé ñòîðîíû, ÿ ñàì íàáëþäàë, êàê äåëàþò èíòðàêðàíèàëüíûå âìåøàòåëüñòâà íåéðîõèðóðãè, èñõîäíî çàíèìàâøèåñÿ îòêðûòûìè îïåðàöèÿìè. Ó íåêîòîðûõ ÿâíî íå õâàòàëî áàçîâûõ êàòåòåðíûõ íàâûêîâ (íàïðèìåð, ïðîâåäåíèå ãàéäà èëè ïðîâîäíèêà ïî èçâèòûì àðòåðèÿì), è îíè òðàòèëè ìíîãî âðåìåíè íà î÷åâèäíûå äëÿ íàñ ñ âàìè âåùè.  îáùåì, ïàëêà î äâóõ êîíöàõ. Íî äóìàþ, â èòîãå ýòî âñå-òàêè îòîéäåò ê íåéðîõèðóðãàì...è ýòî ïðàâèëüíî. |
#11
|
|||
|
|||
 íîÿáðå â Ìîñêâå íà ñúåçäå ñîñóäèñòûõ õèðóðãîâ â èíñòèòóòå Âèøíåâñêîãî áûë äîêëàä èç ñàìàðû ïî ïîâîäó èíòðàêðàíèàëüíîãî ñòåíòèðîâàíèÿ èìåííî ñòåíîçîâ. Äîêëàäûâàë ïðîôåññîð Âà÷åâ. Ìàòåðèàë äîêòîðà Ñóõîðóêîâà (÷åëîâåê, êîòîðûé âûïîëíèë ïåðâóþ ýìáîëèçàöèþ öåðåáðàëüíîé àíåâðèçìû â 1998 (ïî ìîåìó...)). Ìàòåðèàë íåáîëüøîé (÷òî-òî îêîëî 12-15 ÷åëîâåê), ðåçóëüòàòû ñïîðíûå, íàáëþäåíèå íåäîëãîå. Âñå ñòåíòèðîâàíû êîðîíàðíûìè ñòåíòàìè, íî ïðîêñèìàëüíåå Âåëèçèåâà êðóãà. Áûëà î÷åíü êîðîòêàÿ äèñêóññèÿ î òîì ÷åì ñòåíòèðîâàòü, íî áåç îñîáîãî óñïåõà (è êîíôåðåíöèÿ íå ñïåöèàëüíàÿ è âðåìåíè íåáûëî).
Ñ÷èòàþ, ÷òî ïðîêñèìàëüíåå Âåëèçèåâà êðóãà ìîæíî ñòåíòèðîâàòü è êîðîíàðíûìè ñòåíòàìè, ëó÷øå êîáàëüò-õðîì. äèñòàëüíåå âñå-òàêè ñïåöèàëüíûå ñàìîðàñøèðÿþùèåñÿ. Ó ìåíÿ ñîçäàëîñü âïå÷àòëåíèå, ÷òî â îáëàñòè èíòðàêðàíèàëüíîãî ñòåíòèðîâàíèÿ ïðîèçâîäèòåëè ñíà÷àëà ñîçäàþò èíñòðóìåíò, à ïîòîì äóìàþò äëÿ ÷åãî åãî ìîæíî èñïîëüçîâàòü. Ïåðâûå èíòðàêðàíèàëüíûå ñòåíòû ïîçèöèîíèðîâàëèñü êàê äëÿ ðåìîäåëèðîâàíèÿ øèðîêèõ øååê (Leo, Enterpraise, Neuroform), ïîòîì ïîÿâèëñÿ ýëåêòðîëèòè÷åñêè îòäåëÿåìûé Solitare, êîòîðûé ðåøèëè âäðóã èñïîëüçîâàòü êàê ðåòðàêòîð òðîìáîâ (ñåé÷àñ åñòü êàêîé-òî èòàëüÿíñêèé àíàëîã Solitare òîò ïîçèöèîíèðóåòñÿ èñêëþ÷èòåëüíî êàê ðåòðàêòîð). Wingspan ñðàçó ïîçèöèîíèðîâàëñÿ êàê èíòðàêðàíèàëüíûé äëÿ ëå÷åíèÿ ñòåíîçîâ. ßêîáû ðàäèàëüíàÿ óñòîé÷èâîñòü âûñîêàÿ. À åñòü ãäå-íèáóäü ñðàâíåíèå ðàäèàëüíîé óñòîé÷èâîñòè èíòðàêðàíèàëüíûõ ñòåíòîâ ïðåäñòàâëåííûõ íà ðûíêå â Ðîññèè? Åäèíñòâåííûé (ïî ìîåìó) áàëëîíîðàñøèðÿåìûé èíòðàêðàíèàëüíûé ñòåíò ýòî Phoros êîìïàíèè Micrus. Ñòàëüíîé ìàòðè÷íûé î÷åíü ìÿãêèé, êîíöû ïîçîëî÷åííûå äëÿ êîíòðàñòíîñòè. Íî íà ïðåçåíòàöèè ñëîæèëîñü âïå÷àòëåíèå, ÷òî ìåíåäæåðû íå äî êîíöà îñîçíàþò òàêèå ïîíÿòèÿ êàê íîìèíàëüíîå äàâëåíèå, ìåòàëëîíàñûùåííîñòü ñîñóäèñòîé ñòåíêè, ðàäèàëüíàÿ óñòîé÷èâîñòü è ò.ï. Ïðîñòî ñäåëàëè ïîçîëî÷åííóþ øòó÷êó, êîòîðàÿ êðàñèâî ðàñêðûâàåòñÿ â ñèëèêîíîâîì ñîñóäå. Micrus óçêîñïåöèàëèçèðîâàííàÿ êîìïàíèÿ, êîòîðà äåëàåò íåïëîõèå ñïèðàëè, íî â îòíîøåíèè ñòåíòà îíè ìåíÿ óäèâèëè... Ñäåëàë ïÿòü èíòðàêðàíèàëüíûõ ñòåíòèðîâàíèé. Âñå ñ öåëüþ ðåìîäåëèðîâàíèÿ øåéêè àíåâðèçìû. Áåç êàêèõ ëèáî èøåìè÷åñêèõ îñëîæíåíèé. Îòäàëåííûõ ðåçóëüòàòîâ ïîêà íåò âñå â òå÷åíèå ãîäà. Èç ïîðÿäêà 700 öåðåáðàëüíûõ àíãèîãðàôèé âèäåë òîëüêî îäíîãî ïàöèåíòà ñ ìíîæåñòâåííûìè èíòðàêðàíèàëüíûìè ñòåíîçàìè, êîòîðûå ñîâîêóïíî äàâàëè ãåìîäèíàìè÷åñêóþ çíà÷èìîñòü, âìåøèâàòüñÿ íå ðåøèëñÿ, ñóäüáó ïàöèåíòà íå çíàþ. Åùå îêîëî 8 ïàöèåíòîâ èìåëè îäíîñòîðîííèå çíà÷èìûå ñòåíîçû èíòðàêðàíèàëüíûõ àðòåðèé ïðîêñèìàëüíåå Âåëèçèåâà êðóãà. Çíà÷èìîñòü êîìïåíñèðîâàëàñü çà âñ÷åò ïåðåòîêîâ ñ äðóãîé ñòîðîíû, ýíäîâàñêóëÿðíî íå âìåøèâàëèñü. Êà÷åñòâî ýíäîâàñêóëÿðíûõ îïåðàöèé çàâèñèò îò ìàíóàëüíûõ íàâûêîâ è ïðàâèëüíîãî âûáîðà èíñòðåìåíòà. Îò òîãî ãäå âìåøèâàåøüñÿ íà ìîçãå, íà ñåðäöå, íà ñåìåííîé âåíå èëè íà ñîñóäàõ íèæíåé êîíå÷íîñòè çàâèñèò òîëüêî öåíà îøèáêè è îòâåòñòâåííîñòü. ß íå ñ÷èòàþ, ÷òî íåéðîõèðóðãè áîëåå îòâåòñòâåííûå ÷åì èíòåðâåíöèîííûå ðàäèîëîãè... Èíòåðâåíöèîííîãî êàðäèîëîãà íàó÷èòü ýíäîâàñêóëÿðíî ðàáîòàòü íà èíòðàêðàíèàëüíûõ àðòåðèÿõ íàìíîãî ïðîùå è áûñòðåå ÷åì "îòêðûòîãî" íåéðîõèðóðãà. Çäåñü íóæåí òåñíûé òàíäåì, êàê ñ ãèíåêîëîãàìè ïðè ëå÷åíèè ìèîì. Ïîêàçàíèÿ âûñòàâëÿþò íåéðîõèðóðãè ìû îöåíèâàåì òåõíè÷åñêóþ âîçìîæíîñòü, âåðîÿòíûé óñïåõ, âåðîÿòíîñòü îñëîæíåíèé è äåëàåì... Ñ íàèëó÷øèìè ïîæåëàíèÿìè, Ëåâ. |
#12
|
|||
|
|||
Öèòàòà:
From Medscape Medical News > Neurology Intracranial Angioplasty and Stenting Triple Hospital Costs Allison Gandey Ïîñëå ðåãèñòðàöèè íà ðåñóðñå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] îíà äîñòóïíà. |
#13
|
|||
|
|||
 Ñòàâðîïîëå ñòåíòèðîâàíèé èíòðàêðàíèàëüíûõ àðòåðèé íå âûïîëíÿëîñü (ñòåíò-àññèñòåíöèÿ ïðè àíåâðèçìàõ íå ðàññìàòðèâàåòñÿ). Äâóì ïàöèåòàì âûïîíèëè ñòåíòèðîâàíèå ãðàôòîì ïðè àíåâðèçìàõ êàâåðíîçíîãî ñåãìåòà ÂÑÀ, îíîìó èç íèõ óæå âûïëíèëè êîíòðîëü ÷åðåç 6 ìåñ.
|
#14
|
||||
|
||||
Åñëè êîðîòêî:
Öèòàòà:
|
#15
|
||||
|
||||
Citation(s):
The National Institutes of Health. Clinical Alert: Angioplasty combined with stenting plus aggressive medical therapy vs. aggressive medical therapy alone for intracranial arterial stenosis. NINDS stops trial enrollment due to a higher risk of stroke and death in the stented group. Apr 11 , 2011. ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] SAMMPRIS Trial Halted Newly released data suggest that intensive medical management alone is better than angioplasty plus stenting in patients with recently symptomatic, high-grade intracranial arterial stenosis. Patients with symptomatic, severe narrowing of the major intracranial arteries (70%–99% stenosis) have a 25% risk for recurrent stroke within 2 years, despite standard medical therapy with warfarin or aspirin (Circulation 2006; 113:555). In the NIH-sponsored Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial, researchers randomized such high-risk patients to receive angioplasty plus stenting (and aggressive medical management) or to receive aggressive medical management alone. All participants had experienced a transient ischemic attack or nondisabling stroke within the previous 30 days. The Gateway-Wingspan system was used for angioplasty plus stenting. Aggressive medical management comprised daily dual antiplatelet therapy (325-mg aspirin plus 75-mg clopidogrel) for 90 days, followed by aspirin monotherapy (325 mg/day) for the remainder of the study. All patients also received guideline-recommended blood pressure and cholesterol-lowering therapies and were put on a comprehensive lifestyle-modification program. The trial was halted after enrollment of 451 (59%) of the planned 764 participants. An interim review by the trial's Data Safety and Monitoring Board revealed that, within 30 days after enrollment, the rate of stroke or death was higher in the stenting group (14.0%) than in the group who received medical therapy alone (5.8%), higher than in previous studies in which similar subjects had received standard medical treatment, and higher than in relevant registry-comparison groups. All five documented stroke-related deaths within 30 days after enrollment in SAMMPRIS occurred in the stenting group. Comment: Fewer than half of the SAMMPRIS participants have been followed for 1 year, so further data gathering and analysis are required before the findings can be understood in full context. Nonetheless, given these results, angioplasty plus stenting is not the preferred treatment option for patients like those in this trial. These initial results underscore the value of timely, intensive, multimodal risk-factor management, especially given the vagaries of real-world poststroke hospital care and inadequate adherence to appropriate medical therapy (Stroke 2008; 39:1850). Intracranial stenting might still have a very limited role in patients with severe intracranial arterial stenosis who are frequently symptomatic, have extremely poor cerebrovascular reserve, and have failed optimal medical treatment. Journal Watch Neurology May 3, 2011 |